Publicaciones en las que colabora con Javier Pérez Gisbert (37)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

2022

  1. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

    Biomedicines, Vol. 10, Núm. 3

  2. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  3. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  4. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42

2020

  1. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents

    Journal of Gastroenterology and Hepatology (Australia), Vol. 35, Núm. 12, pp. 2080-2087

  2. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

  3. Switching to a second thiopurine in adult and elderly patients with inflammatory bowel disease: A nationwide study from the eneida registry

    Journal of Crohn's and Colitis, Vol. 14, Núm. 9, pp. 1290-1298

  4. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease

    Alimentary Pharmacology and Therapeutics, Vol. 51, Núm. 9, pp. 870-879

  5. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results from the ENEIDA Registry

    Inflammatory Bowel Diseases, Vol. 25, Núm. 11, pp. 1862-1870

  2. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  3. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

  4. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

    Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428

  5. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12

  6. Increased risk of thiopurine-related adverse events in elderly patients with IBD

    Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 7, pp. 780-788

  7. Management and outcomes of patients with Crohn's disease with first vs multiple surgeries: Results from the PRACTICROHN study

    Gastroenterology Report, Vol. 7, Núm. 6, pp. 411-418

  8. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial

    Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535

2018

  1. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 8, pp. 839-851